Home / Content / B2B Connect / Pharma / Lupin receives US FDA nod for generic Evoxac capsule

Lupin receives US FDA nod for generic Evoxac capsule

Evoxac capsule, marketed by Daiichi Sankyo, had recorded sales of $ 40.8 million in the US

Premium

Last Updated : Jan 03 2017 | 10:56 AM IST

Lupin Limited yesterday announced that it has received final approval from the US Food and Drug Administration (FDA) to market its cevimeline hydrochloride capsule (30 mg). Lupin is expected to commence promoting the product shortly.

Cevimeline hydrochloride capsule (30 mg) is a generic version of Daiichi Sankyo Inc’s Evoxac capsule, which is indicated for the treatment of symptoms of dry mouth in patients with Sjogren’s Syndrome. Evoxac capsule had US sales of $ 40.8 million, according to IMS MAT September 2016.

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in